You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance
SBC: EXSCIEN CORPORATION Topic: NIDDKDESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: 300DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A cloud-based secure patient information exchange framework for managing treatment accessibility, utilization, quality, and outcomes in behavioral health clinics
SBC: Waldron International llc Topic: NIDADESCRIPTION In communities across the United States clinical populations exhibiting mental health and or substance abuse disorders face substantial challenges in accessing and receiving high quality and effective behavioral healthcare services Health Information technology HIT has been identified as an important component of improving access to behavioral healthcare in rural communities yet t ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications
SBC: GENECAPTURE, INC. Topic: CBD15C001The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula
STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Clinical real-time resting state fMRI
SBC: NeurInsight, LLC Topic: 108DESCRIPTION provided by applicant Surgical resection of brain neoplasms aims at maximizing long term survival by gross total resection of tumor tissue while preserving the patientandapos s functional status Task based functional MRI fMRI is increasingly used as an adjunct to intra operative electrocorticography for mapping eloquent cortex but suffers a significant failure rate due to funct ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Harvesting specific plant metabolites from hairy root cultures using magnetized n
SBC: NAPROGENIX, INC. Topic: NCCIHDESCRIPTION: Plants produce a wide variety of valuable bioactive metabolites, but these are commonly present in low concentrations in the wild-type plant. This makes the separation and purification of these compounds complicated and expensive. The applicant company, Naprogenix Inc, has developed a technology for increasing the yields of specific bioactive metabolites in mutant plant cell cultures ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial Uncoupling as a Therapeutic Target in Obesity
SBC: Nano-Mite Technologies, LLC Topic: NIDDKDESCRIPTION (provided by applicant): Obesity is recognized as a national and global epidemic, as approximately 65% of adults in the United States are classified as overweight or obese as defined by body mass index (BMI). In fact, in the year 2000, the human race reached a historical landmark, when for the first time in history the number of adults with excess weight surpassed the number of those w ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Compounds for the Prevention and Treatment of Rhabdomyolysis
SBC: Virtual Drug Development Inc. Topic: NIDDK? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health